From June 5 to June 8, 2023, EU GMP auditors conducted the 4-day GMP on-site audit of Aurovitas Pharma Taizhou Co., Ltd.

During the inspection, auditors conducted a comprehensive, meticulous and strict inspection of the quality management, quality control, equipment and facilities, materials, product production, warehousing and personnel of Aurovitas. Three auditors fully affirmed the company's on-site management and gave high praise to the quality and efficient operation of the production system. On site, it was determined that the quality management system of the drugs submitted for review by Aurovitas Pharma Taizhou Co., Ltd. met the EU-GMP requirements, ensuring the compliance and safety of drugs exported to the EU market.

Under the severe epidemic situation, with the support of the group company and under the leadership of leaders at all levels of the company, all employees of Aurovitas Pharma adhere to ideals and principles, are brave to overcome difficulties, resist various inconvenience caused by the epidemic, give full play to their personal strengths, actively and quickly learn from experts in the headquarters and apply. Relying entirely on the strength of Aurovitas, it passed the EU-GMP audit.

Let us extend our high respect and warm congratulations to such admirable employees, respectable leaders, and trustworthy headquarters!